ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem,Andrés Cervantes,René Adam,Alberto Sobrero,J.H.J.M. van Krieken,Dan Aderka,E. Aranda Aguilar,Alberto Bardelli,Al B. Benson,György Bodoky,Fortunato Ciardiello,André D'Hoore,Eduardo Díaz-Rubio,J.-Y. Douillard,Michel Ducreux,Alfredo Falcone,Axel Grothey,Thomas Gruenberger,Karin Haustermans,Volker Heinemann,Paulo M. Hoff,C.-H. Köhne,R. Labianca,Pierre Laurent-Puig,Brigette B.Y. Ma,Tim Maughan,Kei Muro,Nicola Normanno,Pia Österlund,Pia Österlund,Wim J.G. Oyen,Demetris Papamichael,George Pentheroudakis,Per Pfeiffer,Timothy J. Price,C.J.A. Punt,Jens Ricke,Arnaud Roth,R. Salazar,Werner Scheithauer,H.-J. Schmoll,Josep Tabernero,Julien Taieb,Sabine Tejpar,Harpreet Wasan,Takayuki Yoshino,Aziz Zaanan,Dirk Arnold +47 more
TLDR
These ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.About:
This article is published in Annals of Oncology.The article was published on 2016-08-01 and is currently open access. It has received 2382 citations till now.read more
Citations
More filters
Journal ArticleDOI
Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer
Michael J. Overman,Sara Lonardi,Ka Yeung Mark Wong,Heinz-Josef Lenz,Fabio Gelsomino,Massimo Aglietta,Michael A. Morse,Eric Van Cutsem,Ray McDermott,Andrew Hill,Michael B. Sawyer,Alain Hendlisz,Bart Neyns,Magali Svrcek,Rebecca A. Moss,Jean Marie Ledeine,Z. Alexander Cao,Shital Kamble,Scott Kopetz,Thierry André +19 more
TL;DR: Indirect comparisons suggest combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile.
Journal ArticleDOI
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Thierry André,Kai-Keen Shiu,Tae Won Kim,Benny Vittrup Jensen,Lars Henrik Jensen,Cornelis J. A. Punt,Denis Smith,Rocio Garcia-Carbonero,Manuel Benavides,Peter Gibbs,Christelle De La Fouchardiere,Fernando Rivera,Elena Elez,Johanna C. Bendell,Dung T. Le,Takayuki Yoshino,Eric Van Cutsem,Ping Yang,Mohammed Z.H. Farooqui,Patricia Marinello,Luis A. Diaz,Keynote Investigators +21 more
TL;DR: Pembrolizumab led to significantly longer progression-free survival than chemotherapy when received as first-line therapy for MSI-H-dMMR metastatic colorectal cancer, with fewer treatment-related adverse events.
Journal ArticleDOI
Comprehensive review of targeted therapy for colorectal cancer
TL;DR: This review provides an overview of existing CRC-targeted agents and their underlying mechanisms, as well as a discussion of their limitations and future trends.
Journal ArticleDOI
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
Dirk Arnold,B. Lueza,J.-Y. Douillard,Marc Peeters,H. J. Lenz,Alan P. Venook,Volker Heinemann,E. Van Cutsem,Jean-Pierre Pignon,Josep Tabernero,Andrés Cervantes,Andrés Cervantes,Fortunato Ciardiello +12 more
TL;DR: A pooled analysis showed a worse prognosis for OS, PFS and ORR for patients with right-sided tumours in patients with RAS wt mCRC and a predictive effect of tumour side.
Journal ArticleDOI
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Al B. Benson,Alan P. Venook,Mahmoud M. Al-Hawary,Mustafa A. Arain,Yi Jen Chen,Kristen K. Ciombor,Stacey Cohen,Harry S. Cooper,Dustin A. Deming,Linda Farkas,Ignacio Garrido-Laguna,Jean L. Grem,Andrew J. Gunn,J. Randolph Hecht,Sarah E. Hoffe,Joleen M. Hubbard,Steven C. Hunt,Kimberly L. Johung,Natalie Kirilcuk,Smitha S. Krishnamurthi,Wells A. Messersmith,Jeffrey A. Meyerhardt,Eric D. Miller,Mary F. Mulcahy,Steven J. Nurkin,Michael J. Overman,Aparna Raj Parikh,Hitendra Patel,Katrina S. Pedersen,Leonard B. Saltz,Charles Schneider,David Shibata,John M. Skibber,Constantinos T. Sofocleous,Elena M. Stoffel,Eden Stotsky-Himelfarb,Christopher G. Willett,Kristina M. Gregory,Lisa A. Gurski +38 more
TL;DR: The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options for the treatment of metastatic colorectal cancer (mCRC), because important updates have recently been made to this section as discussed by the authors.
References
More filters
Journal ArticleDOI
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
Jacques Ferlay,Isabelle Soerjomataram,Rajesh Dikshit,Sultan Eser,Colin Mathers,Marise Souto Rebelo,Donald Maxwell Parkin,David Forman,Freddie Bray +8 more
TL;DR: The GLOBOCAN series of the International Agency for Research on Cancer (IARC) as mentioned in this paper provides estimates of the worldwide incidence and mortality from 27 major cancers and for all cancers combined for 2012.
Journal ArticleDOI
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
Herbert Hurwitz,Louis Fehrenbacher,William Novotny,Thomas Cartwright,John D. Hainsworth,W. Heim,Jordan Berlin,Ari David Baron,Susan Griffing,Eric Holmgren,Napoleone Ferrara,Gwen Fyfe,Beth Rogers,Robert W. Ross,Fairooz F. Kabbinavar +14 more
TL;DR: The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.
Journal ArticleDOI
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le,Jennifer N. Uram,Hao Wang,Bjarne Bartlett,Holly Kemberling,Aleksandra Eyring,Andrew D. Skora,Brandon Luber,Nilofer S. Azad,Daniel A. Laheru,Barbara A. Biedrzycki,Ross C. Donehower,Atif Zaheer,George A. Fisher,Todd S. Crocenzi,James J. Lee,Steven M. Duffy,Richard M. Goldberg,Richard M. Goldberg,Albert de la Chapelle,Albert de la Chapelle,Minori Koshiji,Feriyl Bhaijee,Thomas Huebner,Ralph H. Hruban,Laura D. Wood,Nathan Cuka,Drew M. Pardoll,Nickolas Papadopoulos,Kenneth W. Kinzler,Shibin Zhou,Toby C. Cornish,Janis M. Taube,Robert A. Anders,James R. Eshleman,Bert Vogelstein,Luis A. Diaz +36 more
TL;DR: This study showed that mismatch-repair status predicted clinical benefit of immune checkpoint blockade with pembrolizumab, and high somatic mutation loads were associated with prolonged progression-free survival.
Journal ArticleDOI
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
J. Ferlay,Eva Steliarova-Foucher,Joannie Lortet-Tieulent,Sonia Rosso,Jan Willem Coebergh,Harry Comber,David Forman,Freddie Bray +7 more
TL;DR: Up-to-date estimates of the cancer burden in Europe alongside the description of the varying distribution of common cancers at both the regional and country level provide a basis for establishing priorities to cancer control actions in Europe.
Journal ArticleDOI
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
David Cunningham,Yves Humblet,Salvatore Siena,David Khayat,Harry Bleiberg,Armando Santoro,D. Bets,M. Mueser,Andreas Harstrick,Chris Verslype,Ian Chau,Eric Van Cutsem +11 more
TL;DR: Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with ir inotecans-refractory colorectal cancer.
Related Papers (5)
The consensus molecular subtypes of colorectal cancer
Justin Guinney,Rodrigo Dienstmann,Rodrigo Dienstmann,Xingwu Wang,Xingwu Wang,Aurélien de Reyniès,Andreas Schlicker,Charlotte Soneson,Laetitia Marisa,Paul Roepman,Gift Nyamundanda,Paolo Angelino,Brian M. Bot,Jeffrey S. Morris,Iris Simon,Sarah Gerster,Evelyn Fessler,Felipe De Sousa E Melo,Edoardo Missiaglia,Hena R. Ramay,David Barras,Krisztian Homicsko,Dipen M. Maru,Ganiraju C. Manyam,Bradley M. Broom,Valérie Boige,Beatriz Perez-Villamil,Ted Laderas,Ramon Salazar,Joe W. Gray,Douglas Hanahan,Josep Tabernero,René Bernards,Stephen H. Friend,Pierre Laurent-Puig,Jan Paul Medema,Anguraj Sadanandam,Lodewyk F. A. Wessels,Mauro Delorenzi,Mauro Delorenzi,Scott Kopetz,Louis Vermeulen,Sabine Tejpar +42 more
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le,Jennifer N. Uram,Hao Wang,Bjarne Bartlett,Holly Kemberling,Aleksandra Eyring,Andrew D. Skora,Brandon Luber,Nilofer S. Azad,Daniel A. Laheru,Barbara A. Biedrzycki,Ross C. Donehower,Atif Zaheer,George A. Fisher,Todd S. Crocenzi,James J. Lee,Steven M. Duffy,Richard M. Goldberg,Richard M. Goldberg,Albert de la Chapelle,Albert de la Chapelle,Minori Koshiji,Feriyl Bhaijee,Thomas Huebner,Ralph H. Hruban,Laura D. Wood,Nathan Cuka,Drew M. Pardoll,Nickolas Papadopoulos,Kenneth W. Kinzler,Shibin Zhou,Toby C. Cornish,Janis M. Taube,Robert A. Anders,James R. Eshleman,Bert Vogelstein,Luis A. Diaz +36 more